Tumor Lysis Syndrome

Tumor Lysis Syndrome (TLS) represents a critical clinical complication occurring when rapidly dividing cancer cells, particularly in aggressive hematologic malignancies like Burkitt’s lymphoma or acute leukemia, die and release intracellular contents into the bloodstream. This massive release triggers hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia, potentially leading to acute kidney injury and fatal arrhythmias. Effective management centers on aggressive hydration with normal saline and the administration of allopurinol to inhibit uric acid production. For high-risk patients, rasburicase provides a potent, albeit expensive, alternative to rapidly degrade uric acid. Clinical monitoring must prioritize serum creatinine and electrolyte levels, while phosphate binders like sevelamer may be necessary to manage calcium-phosphate products. Distinguishing between elevated uric acid levels and actual renal impairment remains essential to avoid unnecessary, costly interventions, ensuring that supportive care strategies remain both clinically effective and resource-efficient.